Abbott India Ltd
- Market Cap ₹ 66,119 Cr.
- Current Price ₹ 31,115
- High / Low ₹ 31,900 / 25,260
- Stock P/E 46.8
- Book Value ₹ 1,992
- Dividend Yield 1.33 %
- ROCE 46.2 %
- ROE 35.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 19.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.2%
- Company has been maintaining a healthy dividend payout of 72.2%
Cons
- Stock is trading at 15.6 times its book value
- The company has delivered a poor sales growth of 9.38% over past five years.
- Working capital days have increased from 28.1 days to 101 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,849 | 6,409 | |
2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,715 | |
Operating Profit | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,082 | 1,206 | 1,453 | 1,695 |
OPM % | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% |
49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 83 | 154 | 248 | 276 | |
Interest | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 |
Depreciation | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 |
Profit before tax | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 |
Tax % | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% |
198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | |
EPS in Rs | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 |
Dividend Payout % | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 9% |
3 Years: | 9% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | 19% |
3 Years: | 21% |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 13% |
3 Years: | 20% |
1 Year: | 17% |
Return on Equity | |
---|---|
10 Years: | 30% |
5 Years: | 32% |
3 Years: | 34% |
Last Year: | 36% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Reserves | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 |
0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | |
351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | |
Total Liabilities | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 |
98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | |
CWIP | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | |
Total Assets | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
155 | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | |
-144 | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | |
-42 | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | |
Net Cash Flow | -31 | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 |
Inventory Days | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 |
Days Payable | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 |
Cash Conversion Cycle | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 |
Working Capital Days | 36 | 30 | 32 | 21 | 63 | 22 | 14 | 7 | -4 | -5 | -12 | 101 |
ROCE % | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - Submission of Secretarial Compliance Report for FY ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 May - Newspaper Publication of Audited Financial Results of the Company for the quarter and year ended on March 31, 2025.
- Record Date For Entitlement Of Dividend 15 May
- Annual General Meeting On August 13, 2025 15 May
-
Announcement under Regulation 30 (LODR)-Dividend Updates
15 May - Abbott India recommends Rs. 475/share final dividend for FY ended March 31, 2025, subject to AGM approval.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Sep 2022TranscriptPPTREC
-
Jun 2021TranscriptPPT
Abbott Group
The company is a part of Abbott Laboratories, USA which has a presence in 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines. [1]